Suven Life Sciences rose 4.42% to Rs 59 at 12:28 IST on BSE after the company announced securing two product patents for its New Chemical Entities in USA and Japan.
The announcement was made during trading hours today, 5 November 2013.
Meanwhile, the S&P BSE Sensex was down 152.28 points or 0.72% at 21,087.08
On BSE, 2.91 lakh shares were traded in the counter as against average daily volume of 2.60 lakh shares in the past one quarter.
The stock hit a 52-week high of Rs 59.50 in intraday trade today, 5 November 2013. The stock hit a low of Rs 55.80 so far during the day. The stock had hit a 52-week low of Rs 22 on 4 March 2013.
The stock outperformed the market over the past one month till 3 November 2013, surging 31.4% compared with the Sensex's 6.72% rise. The scrip had also outperformed the market in past one quarter, advancing 134.93% as against Sensex's 10.83% rise.
Also Read
The small-cap company has equity capital of Rs 11.68 crore. Face value per share is Re 1.
Suven Life Sciences said that the company has today, 5 November 2013 been granted two product patents, one each from the USA and Japan, corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2026 and 2028 respectively.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of 15 granted patents from the USA and seven granted patents from Japan. These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.
Venkat Jasti, CEO of Suven, said We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.
Suven Life Sciences' net profit surged 274% to Rs 29.77 crore on 54.1% growth in net sales to Rs 108.67 crore in Q1 June 2013 over Q1 June 2012.
Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The company has twelve internallydiscovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
Powered by Capital Market - Live News